SCHEMBL13699303

SCHEMBL13699303

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(O[C@H]4CC[C@@H](N(C)C)CC4)cc3)cc2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
MCHR1 Q99705 6/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
NAMPT P43490 1/20 0.41
RECQL P46063 1/20 0.41
USP2 O75604 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699433 0.91 PKM (0.47) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699330 0.89 PKM (0.45) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4236654 0.89 PKM (0.47) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4229212 0.88 MCHR1 (0.51) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4238802 0.87 CYP3A4 (0.42) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4236845 0.86 HRH3 (0.48) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4231912 0.86 PKM (0.45) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4233292 0.86 HRH3 (0.48) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4238227 0.86 MCHR1 (0.46) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL4235333 0.86 SMN1; SMN2 (0.52) PKMRAB9ASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885RAB9A 2492/4885SMN1; SMN2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.